Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Clinical trial NCT04130516 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04130516
- Sponsor
- Linnaeus Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-21
- Primary completion
- 2026-06-30
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.